Type:
Educational Exhibit
Keywords:
Cancer, Diagnostic procedure, PET-CT, Molecular imaging
Authors:
M. M. A. Rezk; Cairo/EG
DOI:
10.26044/ecr2019/C-2625
References
Maxwell,
J.
E.,
& Howe,
J.
R.
(2015).
Imaging in neuroendocrine tumors: an update for the clinician. International journal of endocrine oncology, 2(2),
159-168.Schimmack S,
Svejda B,
Lawrence B,
Kidd M,
Modlin IM.
The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbecks Arch.
Surg. 2011;396(3):273–298. [PubMed]Yao JC,
Hassan M,
Phan A,
et al.
One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J.
Clin.
Oncol. 2008;26(18):3063–3072. [PubMed]Mocellin S,
Nitti D.
Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531) Ann.
Oncol. 2013;24(12):3040–3044. [PubMed]Tsikitis VL,
Wertheim BC,
Guerrero MA.
Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a seer analysis. J.
Cancer. 2012;3:292–302. [PMC free article][PubMed]Imhof A,
Brunner P,
Marincek N,
et al.
Response,
survival,
and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J.
Clin.
Oncol. 2011;29(17):2416–2423. [PubMed]Bushnell DL,
Baum RP.
Standard imaging techniques for neuroendocrine tumors. Endocrinol.
Metab.
Clin.
N.
Am. 2011;40:153–162. [PubMed]